Guangdong True Health, a medical technology company focused on artificial intelligence and life health, builds puncture and ablation surgical robots.
truehealth.cnCrawled Nov 12, 2026
Guangdong True Health Medical Technology Development faces compliance risks in Hong Kong following the death of its secretary. The company, listed as Class H (HK:2697), has disclosed an update regarding potential regulatory gaps. Authorities may scrutinize internal governance and reporting processes amid leadership changes.
TrueHealth Medical reports a more than 30-fold increase in first-half revenue as its surgical robot systems advance into commercial deployment. The company’s robotic surgery platforms are now being actively adopted in clinical settings, marking a shift from development to broader market use. This growth follows the company’s focus on expanding its surgical automation capabilities and scaling production.
Institutional investors are directing capital into Hong Kong’s specialized MedTech firms and niche hardware suppliers tied to AI applications. The focus includes newly listed surgical robot manufacturers and biotech companies advancing clinical progress. While the broader market stagnates, these sectors see heightened scrutiny and funding activity.
Guangdong TrueHealth Medical Technology debuts on the Hong Kong Stock Exchange (HKEX) with a 217% opening surge. The company becomes the first publicly listed firm specializing in percutaneous surgical robotics. The listing marks a significant milestone for minimally invasive robotic surgery technologies.
True Health raises over **RMB 100 million (USD 14M)** in Series B+ funding to advance its surgical robotics technology. The capital supports R&D, AI integration, and procurement of core components for next-generation medical devices. Backed by Gree Group, the company focuses on innovation in minimally invasive surgical solutions.